Saturday 17 October 2026
Export TNGX’s income statement to Excel — free account
Tango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 5.71% and free cash flow fell 4.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
22.04
0.66
−2.91%
Follow TNGX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 16.50 | 14.02 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (34.63) | (30.11) | |
P/B ratio |
— | — | 2.97 | 5.82 | |
Price to Tangible BV |
— | — | 2.97 | 5.82 | |
EV/Sales |
— | — | 10.99 | 11.71 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (4.94) | (5.34) | |
EV/FCF |
— | — | (4.90) | (5.31) | |
Quick Ratio |
49.95 | 26.51 | 15.85 | 8.31 | |
Current Ratio |
50.82 | 27.38 | 16.32 | 8.88 | |
Net Debt/EBITDA |
16.81 | 7.68 | 8.15 | (10.89) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.17 | 0.24 | |
Operating CF/Net income |
0.70 | 0.97 | 0.77 | (1.95) | |
Capex/Depreciation |
(0.04) | 0.00 | 0.77 | 30.20 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 57.27% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 16.58% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 12.31% | |
Graham Net Nets |
— | — | 0.29 | 0.12 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (9.71%) | (10.95%) | |
Free Cash Flow Yield |
— | — | (13.60%) | (15.75%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.48 | |
Operating CF per Share |
(0.26) | (0.31) | (0.26) | (0.28) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.26) | (0.31) | (0.26) | (0.28) | |
Cash per Share |
6.77 | 2.65 | 2.96 | 1.38 | |
Shareholders Equity per Share |
6.84 | 2.73 | 2.98 | 1.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.84 | 2.73 | 2.98 | 1.44 | |
Free Cash Flow |
(38.85) | (44.36) | (29.94) | (31.10) | |
Working Capital |
1,011.37 | 378.00 | 332.08 | 145.34 | |
Capital Expenditures |
0.02 | 0.00 | (0.22) | (0.15) | |
Net Current Asset Value |
982.32 | 348.04 | 301.25 | 113.67 | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
2.21 | 2.83 | 1.39 | 3.17 | |
Average Assets |
655.89 | 355.05 | 357.59 | 281.28 | |
Average Common Equity |
579.74 | 279.13 | 272.85 | 194.60 |
Columns are period end dates